Bavarian Nordic is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company’s clinical pipeline targets cancer and infectious diseases. Bavarian Nordic’s financing requirement derives partly from the requirement for working capital to manufacture IMVAMUNE™ vaccines until expected payments are received under the RFP-3 agreement, and partly from the requirement for funding of the company’s other activities in HIV, cancer, measles, respiratory syncytical virus and immunotherapy.
